Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Standard Biotools (LAB) Equity Average (2016 - 2025)

Standard Biotools (LAB) has disclosed Equity Average for 15 consecutive years, with $412.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average fell 17.55% to $412.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $412.1 million, a 17.55% decrease, with the full-year FY2024 number at $161.8 million, up 241.02% from a year prior.
  • Equity Average was $412.1 million for Q3 2025 at Standard Biotools, down from $439.6 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $543.8 million in Q2 2024 to a low of -$139.9 million in Q4 2023.
  • A 5-year average of $156.5 million and a median of $104.4 million in 2021 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: crashed 1272.4% in 2023, then skyrocketed 616.57% in 2024.
  • Standard Biotools' Equity Average stood at $97.0 million in 2021, then tumbled by 174.36% to -$72.1 million in 2022, then crashed by 94.0% to -$139.9 million in 2023, then skyrocketed by 443.51% to $480.5 million in 2024, then dropped by 14.24% to $412.1 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Equity Average are $412.1 million (Q3 2025), $439.6 million (Q2 2025), and $463.2 million (Q1 2025).